Berlin Workshop 2002

GENETIC INVENTIONS, INTELLECTUAL PROPERTY RIGHTS
AND LICENSING PRACTICES

THIS WORKSHOP IS BY INVITATION ONLY

Berlin, Germany 24-25 January 2002

DAY 1 THURSDAY, 24 JANUARY 2002

08:30 REGISTRATION

09:00-09:15 WELCOMING ADDRESS

Minister Edelgard BULMAHN, Federal Ministry of Education and Research, Germany ( presentation)

09.15-09.30 WORKSHOP GOALS

OECD Opening:John DRYDEN, Deputy Director, Directorate for Science, Technology and Industry, OECD ( presentation)

Workshop Chairman: Joseph STRAUS, Director, Max Planck Institute for Foreign and International Patent, Copyright, and Competition Law, Germany

09:30-10:30 SESSION 1: THE IPR SYSTEM AND ITS RELEVANCE TO GENETIC INVENTIONS

Chair: Christina SAMPOGNA, Industry Canada, Canada

• Ulrich SCHATZ, Principal Director, EPO, Germany ( presentation)
• Alain GALLOCHAT, Ministry of Research, France( presentation)

10:30-11:00 Coffee Break

11:00-12:30 SESSION 2: SURVEYS OF PATENTING AND LICENSING PRACTICES FOR GENETIC INVENTIONS

Chair: Mildred CHO, Stanford University, USA

• Joseph STRAUS, Director, Max Planck Institute, Germany ( presentation)
• John WALSH, Professor, University of Illinois at Chicago, USA ( presentation)
• Fabio PAMMOLLI, Professor, University of Florence, Italy ( presentation)

12:30-14:00 Lunch -- Courtesy of the Federal Ministry of Education and Research, Germany

14:00-15:30 SESSION 3:THE IMPACTS OF PATENTING AND LICENSING PRACTICES ON RESEARCH

Chair: Waldemar KÜTT, European Commission, Belgium

PRO Strategies for Exploitation and Access: research tools, nature identical materials, MTAs, research exemptions, grace periods.

• Maria FREIRE, CEO, The Global Alliance for Drug Development, Belgium, USA, and South Africa( presentation)
• Christian STEIN, Director, Ascenion GmbH, Germany ( presentation)
• Fabirama NIANG, Directeur des Relations Industrielles, Université Louis Pasteur and President, Réseau Curie, France ( presentation)

15:30-16:00 Coffee Break

16:00-18:00 SESSION 4: THE IMPACTS OF PATENTING AND LICENSING PRACTICES ON NEW PRODUCT DEVELOPMENT

Chair: Richard JOHNSON, Arnold & Porter, USA

How Real Are Patent Thickets, Reach-through Rights, Royalty Stacking, and Dependency, and Freedom-to-Operate Restrictions?

• Philip GRUBB, Intellectual Property Council, Novartis International AG, Switzerland ( presentation)
• Jacques WARCOIN, Cabinet Regimbeau, France ( presentation)
• Erik TAMBUYZER, Genzyme Corporation, Belgium ( presentation)

Novel Approaches to IP Management: Consortia, Patent Pools, Collective Rights Organisations

• Lawrence HORN, Vice President MPEG LA, LLC, USA ( presentation)
• Richard JOHNSON, Arnold & Porter, USA

DAY 2 FRIDAY, 25 JANUARY 2002

09:00-10:45 SESSION 5: IMPACTS ON HUMAN HEALTH AND TECHNOLOGY UPTAKE

Chair: Iain Gillespie, OECD, France

Impacts of Patents on Provision of Clinical Genetic Testing Services

• Mildred CHO, Stanford University, USA ( presentation)
• Jeffrey KUSHAN, Powell, Goldstein, Frazer and Murphy, LLP, USA ( presentation)

Possible Policy Responses: Negotiation, Licenses and Opposition

• Richard GOLD, McGill University, Canada
  Bioethics, IPRs, and Human Health ( presentation)
• Ludger HONNEFELDER, University of Bonn, Germany ( presentation)

10:45-11:15 Coffee Break

11:15-13:00 SESSION 6: POLICY ISSUES AND SUMMARY

Chair: Joseph STRAUS, Max Planck Institute, Germany

Rapporteur Review of Key Policy Questions

Stephen CRESPI, United Kingdom

Roundtable Reactions & Policy Recommendations
Selection of speakers and chairs from public research, industry, ethics, health care, and the legal system

• Wes COHEN, Carnegie Mellon University, USA
• Maria FREIRE, The Global Alliance for Drug Development Belgium, United States, and South Africa
• Philip GRUBB, Novartis International AG, Switzerland
  Christian STEIN, Director, Ascenion GmbH, Germany
• Bénédicte CALLAN, OECD, France

Summary of Lessons Learned

Joseph STRAUS, Director, Max Planck Institute, Germany

14:00-16:30 STEERING GROUP AND SPEAKERS: DISCUSSION OF POSSIBLE FUTURE RESEARCH AND ACTIVITIES